The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study

被引：125
|
作者：
Snow, BJ [1 ]
Macdonald, L [1 ]
Mcauley, D [1 ]
Wallis, W [1 ]
机构：
[1] Auckland Hosp, Dept Neurol, Auckland, New Zealand
来源：
CLINICAL NEUROPHARMACOLOGY | 2000年 / 23卷 / 02期
关键词：
amantadine; Parkinson's disease; dyskinesia;
D O I：
10.1097/00002826-200003000-00004
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
We performed a double-blind, placebo-controlled, crossover study to assess the effect of amantadine versus placebo on levodopa-induced dyskinesias in Parkinson's disease. We found a 24% reduction in the total dyskinesia score after amantadine administration (p = 0.004). This improvement was achievement without any influence on the severity of "on" period parkinsonism. The results confirm that amantadine reduces levodopa dyskinesias and support the hypothesis that dyskinesias can be reduced by blockade of excitatory pathways in the basal ganglia.
引用
收藏
页码：82 / 85
页数：4
相关论文
共 50 条
  • [31] Future scenarios for levodopa-induced dyskinesias in Parkinson's disease
    Cerasa, Antonio
    Koch, Giacomo
    Fasano, Alfonso
    Morgante, Francesca
    [J]. FRONTIERS IN NEUROLOGY, 2015, 6
  • [32] Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease
    Cheshire, Perdita A.
    Williams, David R.
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2012, 19 (03) : 343 - 348
  • [33] Levodopa-induced dyskinesias in Parkinson's disease: Is sensitization reversible?
    Bejjani, BP
    Arnulf, I
    Demeret, S
    Damier, P
    Bonnet, AM
    Houeto, JL
    Agid, Y
    [J]. ANNALS OF NEUROLOGY, 2000, 47 (05) : 655 - 658
  • [34] A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease
    Jankovic, J
    Hunter, C
    [J]. PARKINSONISM & RELATED DISORDERS, 2002, 8 (04) : 271 - 276
  • [35] A double blind, placebo-controlled crossover study of the effect of amantadine on chorea in Huntington's disease
    Verhagen, L
    Morris, M
    Farmer, C
    Gillespie, M
    Wuu, J
    Chase, TN
    [J]. NEUROLOGY, 2001, 56 (08) : A386 - A386
  • [36] Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease
    Manson, AJ
    Iakovidou, E
    Lees, AJ
    [J]. MOVEMENT DISORDERS, 2000, 15 (02) : 336 - 337
  • [37] Force overflow and levodopa-induced dyskinesias in Parkinson's disease
    Wenzelburger, R
    Zhang, BR
    Pohle, S
    Klebe, S
    Lorenz, D
    Herzog, J
    Wilms, H
    Deuschl, G
    Krack, P
    [J]. BRAIN, 2002, 125 : 871 - 879
  • [38] Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias
    Cheshire, Perdita
    Ayton, Scott
    Bertram, Kelly L.
    Ling, Helen
    Li, Abi
    McLean, Catriona
    Halliday, Glenda M.
    O'Sullivan, Sean S.
    Revesz, Tamas
    Finkelstein, David I.
    Storey, Elsdon
    Williams, David R.
    [J]. MOVEMENT DISORDERS, 2015, 30 (06) : 796 - 804
  • [39] Clozapine in the treatment of L-dopa induced dyskinesias in Parkinson's disease: A double-blind placebo controlled study (Clozapark)
    Durif, F
    Debilly, B
    Viallet, F
    Rascol, O
    Borg, M
    Broussolle, E
    [J]. MOVEMENT DISORDERS, 2002, 17 : S72 - S72
  • [40] Amantadine treatment of hemispatial neglect - A double-blind, placebo-controlled study
    Buxbaum, Laurel J.
    Ferraro, Mary
    Whyte, John
    Gershkoff, Arthur
    Coslett, H. Branch
    [J]. AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2007, 86 (07) : 527 - 537
12345